Irish access for MS drug offering 'freedom' and 'savings'

3 September 2018

Ireland is the latest European country where patients with highly-active relapsing multiple sclerosis (MS) will have access to Mavenclad (cladribine).

These tablets, from German drugmaker Merck KGaA (MRK: DE), are the first MS treatment that can help reduce relapses for up to four years with a maximum of 20 days oral treatment, taken in the first and second year.

The approval by Ireland’s Health Service Executive to reimburse cladribine tablets follows an assessment by the National Centre for Pharmacoeconomics in July 2018 which considered the treatment to be cost-effective.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK